Ten healthy volunteers received single 2-mg doses of lorazepam on five occasions in random sequence. Modes of administration were: A, intravenous injection; B, deltoid intramuscular injection; C, oral tablets in the fasting state; D, sublingual dosage of oral tablets in the fasting state; and E, sub
Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses
✍ Scribed by G. Caillé; J. Spénard; Y. Lacasse; J. Brennan
- Publisher
- John Wiley and Sons
- Year
- 1983
- Tongue
- English
- Weight
- 484 KB
- Volume
- 4
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
✦ Synopsis
The pharmacokinetic profiles of a sublingual and a conventional oral lorazepam tablet formulation were established following chronic administration to twelve healthy male volunteers. Fitting a multi-dose equation based on a one-compartment model to the observed data, the average elimination half-lives for the sublingual and oral doses are estimated to be 1 1 and 8 h, respectively, while the corresponding absorption half-lives are 15 and 55 min; this confirms earlier reports that the sublingual formulation is more rapidly absorbed.
The observed time to steady-state for both formulations was approximately 3 days, which agrees well with that predicted from previous single dosing studies. Although the sublingual formulation yields a higher average steady-state minimum plasma concentration than the oral formulation (41.6 versus 38.1 ngml-'), the maximum lorazepam concentration achieved during steady state was approximately 83 ng mlfor both formulations. The average steady-state plasma concentration is estimated to be 63 ng ml -', independent of the formulation used.
📜 SIMILAR VOLUMES
The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der
The current research evaluated and compared the efficacy of hydroxybutenyl-b-cyclodextrin (HBenBCD) and hydroxypropyl-b-cyclodextrin (HPBCD) as enhancers of itraconazole solubility and oral bioavailability. At 10 wt% cyclodextrin, 17-fold and 3.8-fold increases in itraconazole aqueous solubility wer
Nine healthy male volunteers took part in a comparison of the pharmacokinetic profiles and effects on psychomotor performance and memory following single dosing with an experimental sustained release (SR) and a conventional release (CR) formulation of lorazepam. There was evidence of a sustained rel